Recent advances in second-trimester abortion: an evidence-based review

American Journal of Obstetrics and Gynecology

Volumn 200, Issue 4, 2009, Pages 347-356

  Hammond, Cassing ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

abortion; mifepristone; misoprostol; pregnancy termination; second trimester

Indexed keywords

CARBOPROST; DIGOXIN; GEMEPROST; METENEPROST; MIFEPRISTONE; MISOPROSTOL; OXYTOCIN; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; SODIUM CHLORIDE; SULPROSTONE; UREA;

CESAREAN SECTION; CLINICAL TRIAL; DILATION AND EVACUATION; DOSAGE SCHEDULE COMPARISON; DRUG COST; DRUG DOSE COMPARISON; DRUG SAFETY; EVIDENCE BASED PRACTICE; FETUS MALFORMATION; HEART INFARCTION; HUMAN; HYSTEROTOMY; LOADING DRUG DOSE; MEDICAL ABORTION; MORTALITY; MULTIPLE PREGNANCY; PLACENTA PREVIA; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; RETAINED PLACENTA; REVIEW; SCAR FORMATION; SECOND TRIMESTER ABORTION; SURGICAL ABORTION; UNITED STATES; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX RIPENING; WATER INTOXICATION;

ABORTIFACIENT AGENTS; ABORTION, INDUCED; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, SECOND;

EID: 62549100870     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2008.11.016     Document Type: Review

References (118)

1. Connell E.B. Preventing the need for second-trimester abortion. In: Berger G., Brenner W., and Keith L.G. (Eds). Second trimester abortion: perspectives after a decade of experience (1971), John Wright PSG Inc, Boston 325
2. Sedgh G., Henshaw S., Singh S., Ahman E., and Shah I.H. Induced abortion: estimated rates and trends worldwide. Lancet 370 (2007) 1338-1345
3. Strauss L., Gamble S., Parker W., et al. Abortion surveillance-United States. MMWR Morb Mortal Wkly Rep 56 SS-91 (2007) 1-33
4. Henshaw S.K., and Finer L.B. The accessibility of abortion services in the United States, 2001. Perspect Sex Reprod Health 35 (2003) 16-24
5. Drey E., Foster D., Jackson R., et al. Risk factors associated with presenting for abortion in the second trimester. Obstet Gynecol 107 (2006) 128-135
6. Finer L.B., Frohwirth L.F., Dauphinee L.A., Singh S., and Moore A.M. Timing of steps and reasons for delay in obtaining abortions in the United States. Contraception 74 (2006) 334-344
7. Medical methods for termination of pregnancy: report of WHO scientific group. Technical report series, No. 871 (1997), World Health Organization, Geneva, Switzerland
8. Grimes D.A., Schulz K.F., and Cates W.J. Prevention of uterine perforation during curettage abortion. JAMA 251 (1984) 2108-2111
9. Stubblefield P.G., Carr-Ellis S., and Borgatta L. Methods for induced abortion. Obstet Gynecol 104 (2004) 174-185
10. Tietze C., and Henshaw S.K. Induced abortion: a world review. 3rd ed. (1986), Alan Guttmacher Institute, New York
11. Kafrissen M.E., Schulz K.F., Grimes D.A., et al. Midtrimester abortion: intra-amniotic instillation of hyperosmolar urea and prostaglandin 5 2 alpha versus dilatation and evacuation. JAMA 251 (1984) 916-919
12. Grimes D.A., Schulz K.F., Cates Jr. W., et al. Mid-trimester abortion by dilatation and evacuation: a safe and practical alternative. N Engl J Med 296 (1977) 1141-1145
13. Hern W.M. Serial multiple laminaria and adjunctive urea in late outpatient dilatation and evacuation abortion. Obstet Gynecol 63 (1984) 543-549
14. Peterson W.F., Berry N., Grace M.R., and Gulbranson C.L. Second-trimester abortion by dilatation and evacuation: an analysis of 11,747 cases. Obstet Gynecol 62 (1983) 185-190
15. Lawson H.W., Frye A., Atrash H.K., et al. Abortion mortality, United States, 1972-1987. Am J Obstet Gynecol 171 (1994) 1365-1372
16. Hoyert D.L. Maternal mortality and related concepts: National Center for Health Statistics. Vital Health Stat 3 (2007) 33
17. Kalish R.B., Chasen S.T., Rosenzweig L.B., Rashbaum W.K., and Chervenak F.A. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol 187 (2002) 882-885
18. Jackson J.E., Grobman W.A., Haney E., and Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gynaecol Obstet 96 (2007) 12-15
19. Freeman E.W. Abortion: subjective attitudes and feelings. Fam Plann Perspect 10 (1978) 150-155
20. Rooks J.B., and Cates W. Emotional impact of D and E vs instillation. Fam Plann Perspect 9 (1977) 276-277
21. Kaltreider N.B., Goldsmith S., and Margolis A.J. The impact of midtrimester abortion techniques on patients and staff. Am J Obstet Gynecol 135 (1979) 235-238
22. Cowett A., Golub R., and Grobman W. Cost-effectiveness of dilation and evacuation versus the induction of labor for second-trimester pregnancy termination. Am J Obstet Gynecol 194 (2006) 768-773
23. Grimes D.A., Smith M.S., and Witham A.D. Mifepristone and misoprostol versus dilation and evacuation for midtrimester abortion: a pilot randomized controlled trial. BJOG 111 (2004) 148-153
24. Eastwood K.L., Kacmar J.E., Steinauer J., Weitzen S., and Boardman L.A. Abortion training in the United States obstetrics and gynecology residency programs. Obstet Gynecol 108 (2006) 303-308
25. Henshaw S.K. Factors hindering access to abortion services. Fam Plann Perspect 27 (1995) 54-59
26. MacIsaac L., Grossman D., Balistreri E., and Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 93 (1999) 766-770
27. Ngai S.W., Chan Y.M., Tang O.S., and Ho P.C. The use of misoprostol for pre-operative cervical dilatation prior to vacuum aspiration: a randomized trial. Hum Reprod 14 (1999) 2139-2142
28. El-Refaey H., Calder L., Wheatley D.N., and Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet 343 (1994) 1207-1209
29. Bugalho A., Bique C., Almeida L., and Bergstrom S. Application of vaginal misoprostol before cervical dilatation to facilitate first trimester pregnancy interruption. Obstet Gynecol 83 (1994) 729-731
30. Todd C.S., Soler M., Castleman L., Rogers M.K., and Blumenthal P.D. Buccal misoprostol for second trimester pregnancy termination. Contraception 65 (2002) 415-418
31. Patel A., Talmont E., Morfesis J., et al. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception 73 (2006) 420-430
32. Goldberg A., Drey E., Whitaker A., Kang M., Meckstroth K., and Darney P. Misoprostol compared with laminaria before early second trimester surgical abortion: a randomized trial. Obstet Gynecol 106 (2005) 234-241
33. Edelman A., Buckmaster J., Goetsch M., Nichols M., and Jensen J. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. Am J Obstet Gynecol 194 (2006) 425-430
34. Darney P.D., and Dorward K. Cervical dilation before first-trimester elective abortion: a controlled comparison of meteneprost, laminaria and hypan. Obstet Gynecol 70 (1987) 397-400
35. Chen J.K., and Elder M.G. Preoperative cervical dilatation by vaginal pessaries containing prostaglandin E1 analogue. Obstet Gynecol 62 (1983) 339-342
36. Lauersen H.N., Den T., Iliescu C., et al. Cervical priming prior to dilatation and evacuation: a comparison of methods. Am J Obstet Gynecol 14 (1982) 890-894
37. Carbonell J., Gallego F., Llorente M., et al. Vaginal vs sublingual misoprostol with mifepristone for cervical priming in second-trimester abortion by dilation and evacuation: a randomized clinical trial 75 (2007) 230-237
38. Riddle J. Contraception and abortion from the ancient world to the Renaissance (1992), Harvard University Press, Cambridge, MA 7-9
39. Potts M. Foreward. In: Baird D., Grimes D., and Van Look P. (Eds). Modern methods of inducing abortion (1995), Blackwell Science Ltd, London ix
40. Kafrissen M.E., Barke M.W., Workman P., et al. Coagulopathy and induced abortion methods: rates and relative risks. Am J Obstet Gynecol 147 (1983) 344-345
41. Kapp N., Todd C.S., Yadgarova K.T., et al. A randomized comparison of misoprostol to intrauterine instillation of hypertonic saline plus a prostaglandin F2 analogue for second trimester induction termination in Uzbekistan. Contraception 76 (2007) 461-466
42. Herabutya Y., and O-Prasertsawat P. Mid-trimester abortion using hypertonic saline or prostaglandin E2 gel: an analysis of efficacy and complications. J Med Assoc Thai 77 (1994) 148-152
43. Nuthalapaty F.S., Ramsey P.S., Biggio J.R., and Owen J. High-dose vaginal misoprostol versus concentrated oxytocin plus low-dose vaginal misoprostol for midtrimester labor induction: a randomized trial. Am J Obstet Gynecol 193 Suppl1 (2005) S1065-S1070
44. Peyron R., Aubeny E., Targosz V., et al. Early termination of pregnancy with mifepristone (Ru-486) and the orally active prostaglandin misoprostol. N Engl J Med 328 (1993) 1509-1513
45. Andersen L.F., Poulsen H.K., Sorensen S.S., Christensen B.M., Sponland G., and Skjeldestad F.E. Termination of 2nd trimester pregnancy with gemeprost vaginal pessaries and intra-amniotic Pgf2-alpha: a comparative study. Eur J Obstet Gynecol Reprod Biol 31 (1989) 1-7
46. Cameron I.T., and Baird D.T. The use of 16,16-dimethyl-trans-delta-2 prostaglandin-E1 methyl-ester (gemeprost) vaginal pessaries for the termination of pregnancy in the early 2nd trimester: a comparison with extra-amniotic prostaglandin-E2. Br J Obstet Gynaecol 91 (1984) 1136-1140
47. Su L.L., Biswas A., Choolani M., Kalaichelvan V., and Singh K. A prospective, randomized comparison of vaginal misoprostol versus intra-amniotic prostaglandins for midtrimester termination of pregnancy. Am J Obstet Gynecol 193 (2005) 1410-1414
48. Owen J., and Hauth J.C. Vaginal misoprostol vs concentrated oxytocin plus low-dose prostaglandin E2 for second trimester pregnancy termination. J Matern Fetal Med 8 (1999) 48-50
49. Nor Azlin M., Abdullah H., Zainul Rashid M., and Jamil M. Misoprostol (alone) in second trimester terminations of pregnancy: as effective as gemeprost?. J Obstet Gynaecol 26 (2006) 546-549
50. Nuutila M., Toivonen J., Ylikorkala O., and Halmesmaki A.E. A comparison between two doses of intravaginal misoprostol and gemeprost for induction of second-trimester abortion. Obstet Gynecol 90 (1997) 896-900
51. Wong K.S., Ngai C.S.W., Wong A.Y.K., Tang L.C.H., and Ho P.C. Vaginal misoprostol compared with vaginal gemeprost in termination of second trimester pregnancy: a randomized trial. Contraception 58 (1998) 207-210
52. Dodd C.M., and Crowther C.A. Misoprostol versus cervagem for the induction of labor to terminate pregnancy in the second and third trimester: a systematic review. Eur J Obstet Gynecol Reprod Biol 125 (2006) 3-8
53. Marinoni E., Santoro M., Vitagliano M.P., Patella A., Cosmi E.V., and Di Iorio R. Intravaginal gemeprost and second-trimester pregnancy termination in the scarred uterus. Int J Gynaecol Obstet 97 (2007) 35-39
54. Neilson J.P., Hickey M., and Vasquez J. Medical treatment for early fetal death (less than 24 weeks). Cochrane Database Syst Rev 3 (2006) OD002253
55. Lalitkumar S., Bygdeman M., and Gemzell-Danielsson K. Mid-trimester induced abortion: a review. Hum Reprod Update 13 (2007) 37-52
56. Blanchard K., Clark S., Winikoff B., Gaines G., Kabani G., and Shannon C. Misoprostol for women's health: a review. Obstet Gynecol 99 (2002) 316-332
57. Jain J.K., and Mishell D.R. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 331 (1994) 290-293
58. Herabutya Y., and Prasertsawat P.O. Second trimester abortion using intravaginal misoprostol. Int J Gynaecol Obstet 60 (1998) 161-165
59. Dickinson J.E., and Evans S.F. The optimization of intravaginal misoprostol dosing schedules in second trimester pregnancy termination. Am J Obstet Gynecol 186 (2002) 470-474
60. Ramin K.D., Ogburn P.L., Daninlenko D.R., and Ramsey P.S. High-dose oral misoprostol for mid-trimester pregnancy interruption. Gynecol Obstet Invest 54 (2002) 176-179
61. Bebbington M.W., Kent N., Lim K., et al. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet Gynecol 187 (2002) 853-857
62. Wong K.S., Ngai C.S.W., Yeo E.L.K., Tang L.C.H., and Ho P.C. A comparison of two regimens of intravaginal misoprostol for termination of second trimester pregnancy: a randomized comparative trial. Hum Reprod 15 (2000) 709-712
63. Ho P.C., Blumenthal P.D., Gemzell-Danielsson K., Gomez Ponce de L.R., Mittal S., and Tang O.S. Misoprostol for the termination of pregnancy with a live fetus at 13 to 26 weeks. Int J Gynaecol Obstet 99 Suppl2 (2007) S178-S181
64. Ashok P.W., Templeton A., Wagaarachchi P.T., and Flett G.M.M. Midtrimester medical termination of pregnancy: a review of 1002 consecutive cases. Contraception 69 (2004) 51-58
65. Borgatta L., Chen A.Y., Vragovic O., Stubblefield P.G., and Magloire C.A. A randomized clinical trial of the addition of laminaria to misoprostol and hypertonic saline for second-trimester induction abortion. Contraception 72 (2005) 358-361
66. Pongsatha S., and Tongsong T. Intravaginal misoprostol for pregnancy termination. Int J Gynaecol Obstet 87 (2004) 176-177
67. Berger G.S., and Kerenyi T.D. Analysis of retained placenta associated with saline abortion: clinical considerations. Am J Obstet Gynecol 120 (1974) 484-488
68. Kirz D.S., and Haag M.K. Management of the 3rd stage of labor in pregnancies terminated by prostaglandin-E2. Am J Obstet Gynecol 160 (1989) 412-414
69. Green J., Borgatta L., Sia M., et al. Intervention rates for placental removal following induction abortion with misoprostol. Contraception 76 (2007) 310-313
70. United Nations Development Program/United Nations Fund for Population Activities/World Health Organization/World Bank Special Program for Research and Development and Research Training in Human Reprod. Annual technical report 1997 (1998), World Health Organization, Geneva, Switzerland
71. World Health Organization. Safe abortion: technical and policy guidance for health systems (2003), World Health Organization, Geneva, Switzerland
72. Royal College of Obstetricians and Gynecologists. The care of women requesting induced abortion (2004), Royal College of Obstetricians and Gynecologists, London
73. Bygdeman M., and Swahn M.L. Progesterone receptor blockage: effect on uterine contractility and early pregnancy. Contraception 32 (1985) 45-51
74. Tang O.S., Chan C.C.W., Kan A.S.Y., and Ho P.C. A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation. Hum Reprod 20 (2005) 3062-3066
75. Rose S.B., Shand C., and Simmons A. Mifepristone- and misoprostol-induced mid-trimester termination of pregnancy: a review of 272 cases. Aust N Z J Obstet Gynaecol 46 (2006) 479-485
76. El-Rafaey H., and Templeton A. Induction of abortion in the second trimester by a combination of misoprostol and mifepristone: a randomized comparison between two misoprostol regimens. Hum Reprod 10 (1995) 475-478
77. Nigam A., Singh V.K., and Prakash A. Vaginal vs oral misoprostol for mid-trimester abortion. Int J Gynaecol Obstet 92 (2006) 270-271
78. Tang O.S., Lau W., Chan C., and Ho P.C. A prospective randomized comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 111 (2004) 1001-1005
79. Webster D., Penney G.C., and Templeton A. A comparison of 600 and 200 mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynaecol 103 (1996) 706-709
80. World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 307 (1993) 532-537
81. Heikinheimo O., Suhonen S., and Haukkamaa M. One- and two-day mifepristone-misoprostol intervals are both effective in medical termination of second-trimester pregnancy. Reprod Biomed Online 8 (2004) 236-239
82. Nilas L., Glavind-Kristensen M., Vejborg T., and Knudsen U.B. One or two day mifepristone-misoprostol interval for second trimester abortion. Acta Obstet Gynecol Scand 86 (2007) 1117-1121
83. Urquhart D.R., and Templeton A.A. The use of mifepristone prior to prostaglandin-induced midtrimester abortion. Hum Reprod 5 (1990) 883-886
84. Kapp N., Borgatta L., Stubblefield P.G., Vragovic O., and Moreno N. Mifepristone in midtrimester medical abortion: a randomized controlled trial. Obstet Gynecol 110 (2007) 1304-1310
85. Jain J.K., and Mishell D.R. A comparison of misoprostol with and without laminaria tents for induction of second-trimester abortion. Am J Obstet Gynecol 175 (1996) 173-177
86. Thong K.J., and Baird D.T. A study of gemeprost alone, Dilapan or mifepristone in combination with gemeprost for the termination of 2nd trimester pregnancy. Contraception 46 (1992) 11-17
87. Ashok P.W., and Templeton A. Nonsurgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. BJOG 106 (1999) 706-710
88. Bartley J., and Baird D.T. A randomized study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG 109 (2002) 1290-1294
89. Hamoda H., Ashok P.W., Flett G.M.M., and Templeton A. A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation. Hum Reprod 20 (2005) 2348-2354
90. Eng N.S., and Guan A.C. Comparative study of intravaginal misoprostol with gemeprost as an abortifacient in second trimester missed abortion. Aust N Z J Obstet Gynaecol 37 (1997) 331-334
91. Dickinson J.E., Godfrey M., and Evans S.F. Efficacy of intravaginal misoprostol in second trimester pregnancy termination: a randomized controlled trial. J Matern Fetal Med 7 (1998) 115-119
92. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 27 (1995) 142-148
93. Winikoff B., Sivin I., Coyaji K.L., et al. Safety, efficacy and acceptability of medical abortion in China, Cuba and India: a comparative trial of mifepristone-misoprostol vs surgical abortion. Am J Obstet Gynecol 176 (1997) 431-437
94. Howie F.L., Henshaw F.C., Naji S.A., Russell I.T., and Templeton A.A. Medical abortion or vacuum aspiration?. Two year follow up of a patient preference trial. BJOG 104 (1997) 829-833
95. Clark W., Shannon C., and Winikoff B. Misoprostol for uterine evacuation in induced abortion and pregnancy failure. Expert Rev Obstet Gynecol 2 (2007) 67-108
96. Wagaarachchi P.T., Ashok P.W., Narvekar N.N., Smith N.C., and Templeton A. A medical management of late intrauterine death using a combination of mifepristone and misoprostol. Br J Obstet Gynaecol 109 (2002) 443-447
97. Fairley T.E., Mackenzie M., Owen P., and Mackenzie F. Management of late intrauterine death using a combination of mifepristone and misoprostol-experience of two regimens. Eur J Obstet Gynecol Reprod Biol 118 (2005) 28-31
98. Jannet D., Aflak N., Abankwa A., Carbonne B., Marpeau L., and Milliez J. Termination of 2nd and 3rd trimester pregnancies with mifepristone and misoprostol. Eur J Obset Gynecol Reprod Biol 70 (1996) 159-163
99. Jackson R.A., Teplin V.L., Drey E.A., Thomas L.J., and Darney P.D. Digoxin to facilitate late second-trimester abortion: a randomized, masked, placebo-controlled trial. Obstet Gynecol 97 (2001) 471-476
100. Hern W.M., Zen C., Ferguson K.A., Hart F.V., and Haseman M.V. Outpatient abortion for fetal anomaly and fetal death from 15-34 menstrual weeks gestation-techniques and clinical management. Obstet Gynecol 81 (1993) 301-306
101. Elimian A., Verma U., and Tejani N. Effect of causing fetal cardiac asystole on second trimester abortion. Obstet Gynecol 94 (1999) 139-141
102. Molaei M., Jones H.E., Weiselberg T., McManama M., Bassell J., and Westhoff C.L. Effectiveness and safety of digoxin to induce fetal demise prior to second-trimester abortion. Contraception 77 (2008) 223-225
103. Rouzi A.A. Second trimester pregnancy termination with misoprostol in women with previous cesarean sections. Int J Gynaecol Obstet 80 (2003) 317-318
104. Debby A., Golan A., Sagiv R., et al. Midtrimester abortion in patients with a previous uterine scar. Eur J Obstet Gynecol Reprod Biol 109 (2003) 177-178
105. Pongsatha S., and Tongsong T. Misoprostol for second trimester termination of pregnancies with prior low transverse cesarean section. Int J Gynaecol Obstet 80 (2003) 61-62
106. Dickinson J.E. Misoprostol for second trimester pregnancy termination in women with a prior cesarean delivery. Obstet Gynecol 105 (2005) 352-356
107. Bhattacharjee N., Ganguly R., and Sha S. Misoprostol for termination of mid-trimester post-cesarean pregnancy. Aust N Z J Obstet Gynaecol 47 (2007) 23-25
108. Daponte A., Nzewenga G., Dimopoulos K.D., and Guidozzi F. The use of vaginal misoprostol for second-trimester pregnancy termination in women with previous single cesarean section. Contraception 74 (2006) 324-327
109. Shammas A.G., and Momani M.D. Misoprostol for termination of second trimester pregnancy in a scarred uterus. Saudi Med J 27 (2006) 1173-1176
110. Mazouni C., Provensal M., Porcu G., et al. Termination of pregnancy in patients with previous cesarean section. Contraception 73 (2006) 244-248
111. Daskalakis G.J., Mesogitis S.A., Papantoniou N.E., Moulopoulos G.G., Papapanagiotou A.A., and Antsaklis A.J. Misoprostol for second trimester pregnancy termination in women with prior cesarean section. BJOG 112 (2005) 97-99
112. Thomas A.G., Alvarez M., Friedman Jr. F., Brodman M.L., Kim J., and Lockwood C. The effect of placenta previa on blood loss in second-trimester pregnancy termination. Obstet Gynecol 84 (1994) 58-60
113. Nakayama D., Masuzaki H., Miura K., et al. Effect of placenta previa on blood loss in second-trimester abortion by labor induction using gemeprost. Contraception 75 (2007) 238-240
114. Thong K.J., Robertson A.J., and Baird D.T. A retrospective study of 932 second trimester terminations using gemeprost (16,16-dimethyl-trans delta2 PGE1 methyl ester). Prostaglandins 44 (1992) 65-74
115. Shulman L.P., Ling F.W., Meyers C.M., Shanklin D.R., Simpson J.L., and Elias S. Dilation and evacuation for second-trimester genetic pregnancy termination. Obstet Gynecol 75 (1990) 1037-1040
116. McMahon JT. Intact D&E: the first decade. Presented at: National Abortion Federation Conference; New Orleans, LA, April 2, 1995. Oral presentation.
117. Haskell M. Dilation and extraction for late second trimester abortion. Presented at: National Abortion Federation Risk Management Seminar. Dallas, TX, September 13, 1992. Oral presentation.
118. Chasen S.T., Kalish R.B., Gupta M., Kaufman J.E., Rashbaum W.K., and Chervenak F.A. Dilation and evacuation at > or=20 weeks: comparison of operative techniques. Am J Obstet Gynecol 190 (2004) 1180-1183